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AIM:  Behçet’s  disease  (BD)  is  a  systemic  immuno-
inflammatory disorder and the aetiopathogenesis is
to  be  specified.  Cytokines  play  a  role  in  immune
response and  in  many  inflammatory  diseases. The
aim of this case–control study is to investigate serum
pro-inflammatory  cytokine  tumour  necrosis  factor
(TNF)-a , interleukin-1beta (IL-1b ), soluble IL-2 recep-
tor  (sIL-2R),  IL-6,  and  chemokine  IL-8  levels  in
patients with BD. We also determined the end product
of lipid peroxidation (malondialdehyde (MDA)) in BD
patients as an index for oxidative stress.
Methods: A total of 37 patients (19 men, 18 women)
with BD (active, n = 17; inactive, n = 20) and 20 age-
matched  and  sex-matched  healthy  control  subjects
(11  men,  nine  women)  included  in  this  cross-sec-
tional, blinded study. Serum TNF-a , IL-1b , sIL-2R, IL-6
and  IL-8  levels  were  determined by  a  spectrophot-
ometer technique using the immulite chemilumines-
cent  immunometric  assay.  Lipid  peroxidation  was
evaluated by Wasowicz et al. The levels of cytokines
and  lipid  peroxidation  in  the  active  period  were
compared  with  the  inactive  period  of  the  disease.
Results are expressed as mean ± standard error.
Results: IL-1b levels were below the detection limits
of the assay (< 5pg/ml) in all samples. Mean levels of
MDA (8.1 ± 0.7m mol/l), sIL-2R (800 ± 38U/ml), IL-6
(12.6 ± 1.1pg/ml), IL-8 (7.2 ± 0.4pg/ml), and TNF-a
(7.9  ±  0.5pg/ml)  in  active  BD  patients  were  sig-
nificantly higher than those in inactive patients (4.3 ±
0.5m mol/l, p < 0.01; 447 ± 16U/ml, p < 0.001; 8.3 ±
0.6pg/ml, p = 0.006; 5.3 ± 0.1pg/ml, p < 0.001; and 5.1
±  0.2pg/ml,  p  <  0.001;  respectively)  or  control
subjects (2.1 ± 0.2m mol/l, p < 0.001; 446 ± 20U/ml, p
< 0.001; 6.4 ± 0.2pg/ml, p < 0.001; 5.4 ± 0.1pg/ml, p <
0.001; and 4.7 ± 0.1pg/ml, p < 0.001, respectively). On
the  contrary,  only  the  mean  IL-6  level  was  sig-
nificantly different between inactive BD and control
subjects  (p  =  0.02).  All  acute  phase  reactants  were
significantly  higher  in  active  BD  than  in  inactive
period (for each, p < 0.01).
Conclusions: High levels of sIL-2R, IL-6, IL-8 and TNF-a
indicate  the  activation  of  immune  system  in  BD.
Serum sIL-2R, IL-6, IL-8 and TNF-a seem to be related
to disease activity. Increased lipid peroxidation sug-
gests  oxidative  stress  in  BD  and  therefore  tissue
damage  in  such  patients.  Amelioration  of  clinical
manifestations would be envisaged by targeting these
cytokines, chemokines and lipid peroxidation with
pharmacological agents.
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Introduction
Cytokines  are  low  molecular  weight  polypeptides
involved  in  the  communication  between  cells.1
Abnormal  production  of  some  cytokines  such  as
tumour necrosis factor (TNF)-a, interleukin-1beta (IL-
1b),  soluble  IL-2 receptor (sIL-2R),  IL-6,  and chem-
okine IL-8 have been implicated in the pathogenesis
of various inflammatory and autoimmune diseases.1,2
Many in vivo studies have demonstrated that TNF-a,
IL-1, IL-6, and IL-8 are all important components of
the  pro-inflammatory  response  and  intraocular
inflammation.2 Oxidative  stress  is  associated  with
many systemic inflammatory diseases, and free-radical
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lipid peroxidation.3
Behçet’s disease (BD)  is a systemic inflammatory
disorder of young adults involving small blood vessels
(veins and arteries) and is characterised by occlusion
in both the deep venous and retinal circulations with
unknown aetiology.4After its first description as oral
and genital ulceration with hypopyon uveitis in 1937
by the Turkish physician Prof. Dr Hulusi Behçet,5 the
multisystem  character of  the disease has well been
established.4 The  classical  ocular  involvement  is
iridocyclitis, anterior hypopyon uveitis, retinal vascu-
litis or panuveitis. In severe ocular disease, the visual
prognosis is poor and blindness may occur despite
immunosuppressive treatment. Although the aetiopa-
thogenesis of the disease has not yet been clarified,
several  mechanisms  such  as  genetics,  infection,
immunoglobulin, immune complexes and antibodies
have  all  been  suggested  as  the  causes  of  BD.4,6 It
affects  almost  every  tissue  and  organ  in  the  body
without exception, including the cornea,7 inner ear8
and the lung.9The intermittent nature and the lack of
consistent response to therapy make the underlying
aetiology difficult to define.
Our  previous  studies  demonstrated  that  some
molecules  such  as  adrenomedullin,10 leptin,11 and
homocysteine12 might participate during the course
of BD. Furthermore, our more recent study showed
that nitric oxide (NO), one of the most abundant free
radicals in the body, was significantly increased in BD
and associated with disease activity, suggesting a new
activity  marker.13 Since  pro-inflammatory  cytokines
are known to be the potent inducer of leptin and,
therefore, NO from the endothelial cells, it is impor-
tant to study the levels of these cytokines as well as
lipid peroxidation products as a cohort study during
the course of BD. Similarly, homocysteine enhances
NO  synthesis  from  endothelial  cells,  induces  the
expression of chemoattractants by oxygen free radi-
cals,  and  has  important  interrelations  with  cyto-
kines.14 Therefore, this study has attempted to over-
come  these  limitations  in  our  understanding  by
measuring  the  serum  levels  of  pro-inflammatory
cytokines  such  as  TNF-a,  IL-1b,  sIL-2R,  IL-6  and
chemokine IL-8 as well as lipid peroxidation, linking
to the state of disease activity. We wished to test the
hypothesis that no one factor alone is predominant in
the pathophysiology during the course of BD, but that
a regular profile of levels of different molecules might
be  operating  together,  and  that  the  profile  might
differ according to disease activity.
Patients and methods
Study population
Thirty-seven consecutive patients with BD (19 men,
18 women; mean age, 37.2 years) who attended to
the Department of Ophthalmology and/or the Depart-
ment of Dermatology, and 20 age-matched and sex-
matched  healthy  control  subjects  (11  men,  nine
women; mean age, 38.4 years) from a similar ethnic
background were included in this study. Subjects with
any  disorder  such  as  hepatic  or  renal  diseases,
diabetes,  essential  hypertension  and  pregnancies
were  excluded  from  the  study.  Since  medications
such as glucocorticosteroids reduce the transcription
of the pro-inflammatory cytokines (IL-1, IL-2, IL-6, IL-
8, and TNF-a),15 a detailed history of drug use was
obtained in both groups and, as such, three patients
using  steroids  and  two  patients  using  immunosup-
pressives were not included in the study. The diag-
nosis of BD was made according to the criteria for
diagnosis of the International Study Group for Beh-
çet’s  Disease16 (Table  1).  Informed  consent  was
obtained from all subjects in both groups.
Nineteen  patients  (51.3%)  had  severe  ocular
involvement (anterior hypopyon uveitis/iridocyclitis,
retinal vasculitis, cells in the vitreous, or panuveitis).
In  addition,  oral  lesions  were  present  in  all  cases
(100%).  Thirty-four  patients  (91.8%)  had  various
coetaneous lesions. Articular symptoms were present
in  33  patients (89.1%)  and genital  ulceration in  31
(83.7%).  Eighteen of  37  patients (48.6%)  showed a
positive  pathergy  test,  nine  patients  (24.3%)  com-
plained of neurological symptoms and one of them
(2.7%)  had  Neuro-Behçet’s.  Gastrointestinal  system
symptoms and signs  were present in  eight patients
(21.6%).
Since  there  is  no  clinically  acceptable  scoring
system and laboratory screening profile to define the
severity of BD, active (n = 17) and inactive (n = 20)
BD  patients  were  determined  by  both  clinical  and
laboratory findings. In clinical evaluation, worsening
of clinical symptoms at the time of study and having at
least three of the major symptoms (oral ulcers, genital
ulcers, skin lesions and uveitis) were considered to be
in  the  active  period  of  the  disease.  The  inactive
patients had no any symptoms and signs of disease
activity  at  least  3  months  before  admission.  The
diagnosis  of  uveitis  was  made  according  to  the
International  Uveitis  Study  Group.17 In  laboratory
investigations,  the  erythrocyte  sedimentation  rate
(ESR),  neutrophil  count  and  acute  phase  reactants
(a1-antitrypsin and a 2-macroglobulin concentrations)
were investigated.10–13
Neutrophil count, ESR and acute-phase
reactants analyses
This  was  a  double-blind  study. Therefore,  both  the
physician  taking  the  blood  and  the  analyser  were
blinded to the group of the subject. In both groups,
antecubital  whole  blood samples (total, 5ml)  were
obtained  by  venipuncture  from  a  peripheral  vein,
avoiding haemolysis, into plain tubes during resting
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criteria* for the diagnosis of Behçet’s disease
No. Sex A D Ou Coetaneous lesions Gu Path.‡ Ocular lesions Other findings
1† M 38 8 + Pseudofolliculitis, acneiform lesions – + Right retinal vasculitis Migraine headache
2 W 44 16 + Erythema nodosum, pseudofolliculitis + + – Arthralgia at the knees
Acneiform lesions ALP
3† W 22 2 + Pseudofolliculitis, acneiform lesions – + – Arthralgia at the ankles
4† M 45 12 + Pseudofolliculitis, acneiform lesions + – Left anterior iridocyclitis Arthritis at the knees
5 M 52 24 + – + – Bilateral panuveitis Migraine headache
Sacroiliitis
6† W 52 21 + Erythema nodosum, pseudofolliculitis – + – Neuro-Behçet’s, arthralgia at the
knees and ankles
7 W 35 6 + Acneiform lesions + + – Arthralgia at the knees
8 M 34 7 + Pseudofolliculitis, acneiform lesions + + – Arthralgia at the knees
9† M 29 4 + Acneiform lesions, thrombophlebitis + – Right hypopyon uveitis Arthritis at the knees
10 M 26 3 + Pseudofolliculitis, acneiform lesions + – Left retinal vasculitis Arthritis at the ankles
11 W 44 10 + Erythema nodosum, thrombophlebitis
Pseudofolliculitis, acneiform lesions
+ + – Sacroiliitis
ALP
12† M 33 f8 + Pseudofolliculitis, acneiform lesions + – Bilateral retinal vasculitis Migraine headache
13 M 32 7 + Thrombophlebitis, pseudofolliculitis + – – ALP
14 W 25 3 + Pseudofolliculitis, acneiform lesions + + – Swelling in both knees
15† W 45 12 + – + + Left hypopyon uveitis Arthritis at the knees
16† M 36 11 + Pseudofolliculitis, acneiform lesions + + Bilateral vitreal cells
Right hypopyon uveitis
Arthralgia at the ankles
ALP
17 W 26 2 + Pseudofolliculitis, acneiform lesions + + – Migraine headache, Arthralgia at
the knees
18 W 52 21 + Erythema nodosum, thrombophlebitis + – Bilateral retinal vasculitis Arthralgia at the knees
19† M 45 15 + Erythema nodosum, thrombophlebitis
Acneiform lesions
+ + – Melena
Arthralgia at the right knee
20 M 45 17 + Pseudofolliculitis + – Bilateral retinal vasculitis Arthralgia at the knees
21 M 34 8 + Erythema nodosum + – Right iridocyclitis Arthritis at the ankles and fingers
22† W 56 25 + Erythema nodosum, thrombophlebitis
Pseudofolliculitis, acneiform lesions
+ + – Sacroiliitis
23 W 25 3 + Erythema nodosum, thrombophlebitis
Pseudofolliculitis, acneiform lesions
+ – – Migraine headache
24 M 36 11 + – + – Bilateral retinal vasculitis Arthralgia at the knees and fingers
Left anterior uveitis
25 W 35 9 + Thrombophlebitis, pseudofolliculitis
Acneiform lesions
– + Bilateral iridocyclitis Melena
Arthralgia at the knees
26† W 19 1 + Pseudofolliculitis, acneiform lesions + + – Arthralgia at the knees and fingers
27† M 33 9 + Pseudofolliculitis, acneiform lesions + – Bilateral retinal vasculitis Arthralgia at the knees
28† W 38 11 + Pseudofolliculitis, acneiform lesions + – – Arthralgia at the fingers
29 W 36 7 + Pseudofolliculitis + – – Migraine headache
Arthralgia at the fingers
30† M 31 5 + Thrombophlebitis, pseudofolliculitis
Acneiform lesions
+ – Left retinal vasculitis Arthralgia at the knees
ALP
31 W 46 15 + Erythema nodosum, thrombophlebitis
Pseudofolliculitis
+ – – Ankylosing spondylitis
ALP
32 M 26 3 + Pseudofolliculitis, acneiform lesions – + – Arthralgia at the knees
33† M 45 13 + Erythema nodosum, pseudofolliculitis
Acneiform lesions
+ – Right iridocyclitis Arthralgia at the knees
34† W 41 15 + Thrombophlebitis, pseudofolliculitis
Acneiform lesions
+ – Left anterior uveitis Arthralgia at the knees and ankles
35 M 41 12 + Pseudofolliculitis, acneiform lesions + + Bilateral iridocyclitis Migraine headache
Arthralgia at the left knee
36 W 32 8 + Pseudofolliculitis, acneiform lesions – + – Migraine headache
Arthralgia at the right knee
37† M 36 11 + Erythema nodosum, pseudofolliculitis + – Bilateral iridocyclitis Arthralgia at the knees
A, Age (years); D, disease duration (years); Ou, recurrent oral aphthous ulceration; Gu, recurrent genital ulceration; Path., pathergy test;M, men;
W, women, ALP, appendicitis-like pain.
*Ou plus two of the following criteria (Gu, ocular lesions, coetaneous lesions, pathergy test positivity).
†Active patients with Behçet’s disease.
‡Observation of a pustular lesion by physician at 24–48h after needle-stick.
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overnight fast and 30min of supine rest. None of the
patients and healthy control subjects was receiving any
topical or systemic medication on admission. Follow-
ing centrifugation of the first half of the blood samples
(2.5ml) at 800 ´ gfor 10min, serum was separated and
kept at –20°C until the time of analysis.
The other half of the blood samples (2.5ml), with
ethylenediamine tetraacetic acid (1mg/ml) anticoagu-
lant  was  used  for  the  neutrophil  counting  by  an
automated blood counter (Coulter-STKS, Luton, UK).
a1-Antitrypsin  and  a2-macroglobulin  concentrations
were  measured in  the  serum  by  a Behring  nephel-
ometer  100  analyser  (Dade  Behring,  Messer  Grie-
sheim, Frankfurt, Germany). The ESR was determined
by the classical Westergren method.
Cytokine and chemokine analyses
Cytokine  analysis  was  performed  according  to  the
Immulite®  (Diagnostic  Products  Corporation,  Los
Angeles, CA, USA) chemiluminescent enzyme immu-
nometric assay. The technique is based on a solid-phase
(bead) two-site assay. The solid phase, a polystyrene
bead,  is  coated  with  either  a  monoclonal  specific
antibody (TNF-a, IL-1b) or an anti-ligand (sIL-2R, IL-6,
IL-8). Patient serum and alkaline phosphatase-conju-
gated monoclonal antibody or ligand-labelled antibody
are  incubated  for  30–60min  at  37°C.  Unbound
conjugate is then removed by a centrifugal wash (three
times), after which a chemiluminescent substrate (a
phosphate ester of adamantyl dioxetane) is added and
the test unit is incubated for  a further 10min. The
Immulite  system  automatically  handles  sample  and
reagent additions, the incubation and separation step,
and  measurement  of  the  photon  output  via  the
temperature-controlled luminometer. It calculates test
results  for  control  and  patient  samples  from  the
observed  signal,  using  a  stored  master  curve,  and
generates a printed report.18The values of the inter-
assay imprecision study were similar to those from the
intra-assay  study  with  coefficient  of  variation  (CV)
ranging  from  2  to  11.5%.  CVs  for  the  measured
cytokines  were  usually  around  5%. The  linearity  is
satisfactory, with a regression coefficient higher than
0.99 (r2); slopes close to 1.0 were obtained.  There is an
excellent practicality of the system and good stability
of the calibration curve (15 days). It is a good reliable
method  yielding  a  good  precision  along  with  a
satisfactory detection limit.19 The antibodies used in
the Immulite®for  TNF-a, IL-1b, sIL-2R, IL-6, and IL-8 are
highly specific for each cytokine and chemokine, with
no  cross-reactivity  to  other  cytokines  that  may  be
present in the serum samples.
For each new cytokine calibration, a master curve
is constructed by the manufacturer using a material
calibrated against the National Institute for Biological
Standards and Control. For each new cytokine reagent
lot, an adjustment of the calibration slope is made by
the user by measuring two serum matrix vials (low
and  high)  designated  as  ‘adjusters’.  It  should  be
mentioned that between-run and within-run impreci-
sion data were similar, which is very important for stat
measurement.
Thiobarbituric acid-reactive substances analysis
The plasma malondialdehyde (MDA) level, referred to
as  thiobarbituric  acid-reactive  substances  (TBARS),
was measured according to the method described by
Wasowicz  et  al.20 In  brief,  50ml  of  sample  or  an
adequate volume of MDA working standard solution
was introduced into 10ml glass tubes containing 1ml
of distilled water. After addition of 1ml of the solution
containing  29mmol/l  of TBARS  in  acetic  acid  and
mixing, the samples were placed in a water bath and
heated for 1h at 95–100°C. After the samples were
cooled,  25ml  of  5mol/l  HCl  was  added,  and  the
reaction mixture was extracted by agitation for 5min
with  3.5ml  of  n-butanol.  The  butanol  phase  was
separated by centrifugation at 1500 ´ g for 10min.
The  butanol  extract was  measured  with  a  spectro-
fluorometer  (F-4010  fluorescence  spectrophotom-
eter; Hitachi, Tokyo, Japan) at wavelengths of 525nm
for  excitation. The  calibration  curve  was  prepared
with MDA standards of 0–10mmol/l. Intra- and inter-
assay CVs were 3.5 and 6%, respectively.
Statistical analysis
Results were analysed statistically by using the analysis
of variance or the Mann–Whitney U-test as indicated,
and were expressed as mean ± standard error (range).
p <  0.05  was  considered  a  significant  difference
between the groups. Statistical analysis was performed
with the Statistical Package for the Social Sciences for
Windows (version 8.0; SPSS Inc., Chicago, IL, USA).
Results
For IL-1b, all samples in both groups were below the
detection limits of the assay (< 5pg/ml). sIL-2R levels
ranged from 347 to 1076U/ml, with the highest values
observed  in  the  active  BD  patients.  Mean  sIL-2R
concentration in active BD patients was 800 ± 38U/ml
and  the  difference  was  significant  when compared
with inactive patients (447 ± 16U/ml, p < 0.001) or
healthy control subjects (446 ± 20U/ml, p < 0.001)
(Table  2).  IL-6  concentrations  ranged  from  5  to
22.5pg/ml, with the highest values observed in the
active  BD  patients,  and  the  mean  values  in  active
patients (12.6 ± 1.1pg/ml) were significantly higher
than those in inactive patients (8.3 ± 0.6pg/ml, p =
0.006) or control subjects (6.4 ± 0.2pg/ml, p < 0.001).
Mean IL-8 concentrations were found to be higher in
patients  with  active  BD  (7.2  ±  0.4pg/ml)  than  in
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and control subjects (5.4 ± 0.1pg/ml, p < 0.001). The
highest  TNF-a concentrations  were  observed  in
patients with active BD and the mean value (7.9 ±
0.5pg/ml) was significantly higher than inactive BD
(5.1 ± 0.2pg/ml, p < 0.001) or control subjects (4.7 ±
0.1pg/ml,  p <  0.001).  Mean  MDA  levels  were  also
significantly higher in active BD (8.1 ± 0.7mmol/l) than
in inactive BD (4.3 ± 0.5mmol/l, p < 0.01) or control
subjects (2.1 ± 0.2mmol/l, p < 0.001). Mean MDA, sIL-
2R, IL-8 and TNF-a levels in patients with inactive BD
were not higher (for each, p > 0.05) when compared
with the control subjects, unlike IL-6 (p = 0.02).
There were statistically significant  (for  each, p <
0.01)  differences for acute-phase reactants between
active and inactive periods of the disease (Table 3).
Discussion
The main pathology in BD is an inflammatory process
of small arteries and veins and thrombosis as a result
of  vasculitis  of  the  vaso  vasorum.21 The  immune
system  is  involved  and  activated  in  the  course  of
disease,  since  increased  immunoglobulins,  immune
complexes,  complement  and  acute  phase  proteins
have  all  been  reported.4,6 Abnormalities  of  neu-
trophils,  endothelial cells,  or  both,  have been  sug-
gested  to  be  responsible  for  many  of  the  clinical
manifestations of BD.22Activation of circulating T and
B lymphocytes also occurs, and these immunoactive
cells infiltrate into the affected regions followed by a
second phase of neutrophil chemotaxis.4,6 Although
there is no definitive treatment of BD, hydrocortisone,
colchicine, cyclosporin and cyclophosphamide have
been used to subside the symptoms and signs of the
disease.4,6 Given this immunological  activity in BD,
pro-inflammatory  cytokines  and  mediators  may  be
effected in the course of the disease.
IL-1b (17kDa)  regulates  systemically  the  meta-
bolic,  immuno-inflammatory  and  reparative  proper-
ties, and can be a mediator of some diseases.23 It is
secreted by monocytes and tissue macrophages, and
is involved in the activation of T cells.24 Control of
IL-1  synthesis  or  its  effects  becomes  a  target  of
therapy  in  many  diseases.25 However,  this  study
showed that IL-1b levels of BD patients and control
subjects were below the detection limits of the assay
(5pg/ml) in  all samples.
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Table 2. MDA, TNF-a, IL-1b, sIL-2R, IL-6 and IL-8 levels in patients with Behçet’s disease and control subjects, and the relation
with disease activity
Group n Age
(years)
(range)
Men/
women
MDA
(mmol/l)
(mean
6 SE)
IL-1b
(pg/ml)
(mean
6 SE)
sIL-2R
(U/ml)
(mean 6
SE [range])
IL-6
(pg/ml)
(mean 6
SE [range])
IL-8
(pg/ml)
(mean 6
SE [range])
TNF-a
(pg/ml)
(mean 6
SE [range])
Active BD* 17 37.8
(19–56)
10/7 8.1 ± 0.7 < 5.0 800 ± 38
(465–1076)
12.6 ± 1.1
(6.0–22.5)
7.2 ± 0.4
(5.2–11.2)
7.9 ± 0.5
(4.9–12.2)
p value† < 0.01 NS < 0.001 0.006 < 0.001 < 0.001
Inactive BD 20 36.3
(25–52)
9/11 4.3 ± 0.5 < 5.0 447 ± 16
(347–563)
8.3 ± 0.6‡
(5.0–14.7)
5.3 ± 0.1
(5.0–6.5)
5.1 ± 0.2
(4.0–7.4)
p value‡ NS NS NS 0.02 NS NS
Control
subjects
20 38.4
(25–56)
11/9 2.1 ± 0.2 < 5.0 446 ± 20
(248–605)
6.4 ± 0.2
(5.0–8.5)
5.4 ± 0.1
(5.0–7.4)
4.7 ± 0.1
(4.0–7.1)
NS, not significant; SE, standard error.
*Mean values for all parameters (except IL-1b) were significantly (for each, p < 0.001) higher than control subjects by analysis of variance.
†Statistical values between active and inactive BD subjects by analysis of variance.
‡Statistical values between inactive patients and control subjects by analysis of variance.
Table 3. Neutrophil count, erythrocyte sedimentation rate and acute-phase reactant levels in patients with active or inactive
Behçet’s disease compared with control subjects
Active BD
(n = 17)
Inactive BD
(n = 20)
Controls
(n = 20)
Neutrophil Count (10
3/ml) 6.2 ± 0.3*† 3.4 ± 0.1† 2.9 ± 0.1
Erythrocyte sedimentation rate (mm/1h) 36.0 ± 1.6*† 20.4 ± 0.7† 9.9 ± 0.6
a1-Antitrypsin (mg/dl) 231.7 ± 8.3*† 160.4 ± 4.0† 127.2 ± 3.2
a2-Macroglobulin (mg/dl) 275.5 ± 6.1*† 214.9 ± 3.5† 159.7 ± 5.7
Data presented as mean ± standard error.
*Significantly different from the inactive period by analysis of variance (for each, p < 0.01).
†Significantly different from the control subjects by Mann–Whitney U-test (for each, p < 0.01).The sIL-2R is a smaller (45kDa) polypeptide than
the  membrane-bound  IL-2R  (55kDa),  and  has  a
potential role in the modulation of immune responses
by inhibiting IL-2.26 Immunosuppressive agents such
as  hydrocortisone,  cyclosporin  and  cyclophospha-
mide, which are widely used in the treatment of BD,
downregulate the synthesis of IL-2.4 Clinically, high
levels of sIL-2R are believed to be associated with a
potent  activation  of  the  immune  system  in  many
diseases such as atopic dermatitis and psoriasis.27 In
the  present  study,  serum  levels  of  sIL-2R  were
significantly  higher in patients with BD when com-
pared with control subjects. In addition, serum sIL-2R
levels were significantly higher in active patients than
in inactive patients with BD. We think that high serum
levels  of  sIL-2R  in  the  active  period  indicate  the
activation of the immune system in BD and may have
a pathophysiological role in the course of the disease.
Inactive patients showed no significant elevation of
serum sIL-2R levels over control subjects.
IL-6 (26kDa) is a multifunctional pro-inflammatory
cytokine with its important role in the regulation of
immune  response.28 It  is  produced  by  monocytes,
epithelial cells and fibroblasts, and causes polyclonal
B-cell  activation,  hypergammaglobulinaemia,  and
autoantibody production with T-cell activation.29The
major effect of IL-6 described is the proliferation and
differentiation of cells, as well as increasing secretion
of acute-phase proteins by the liver.27 It has also been
reported that IL-6 induces uveitis in vivo in rats when
injected  intracamerally.30 Abnormal  IL-6  production
has  been  implicated  in  some  autoimmune  diseases
and  chronic  inflammatory  reactions.31 Our  study
showed  that  patients  with  BD  had  significantly
elevated IL-6 levels compared with control subjects,
with the highest values observed in the active period
of the disease. In addition, even inactive patients with
BD  had  significantly  higher  IL-6  levels  when  com-
pared  with  control  subjects.  Since  IL-6  is  a  key
activator of the acute-phase response and implicated
in liver synthesis of acute-phase reactants,31 it is likely
to play an important role in the course of BD.
IL-8, a chemokine secreted from many cells includ-
ing endothelial cells, lymphocytes, monocytes, mac-
rophages and retinal pigment epithelial (RPE) cells, is
one of the main chemoattractants for polymorphonu-
clear neutrophils (PMNs) and can also directly acti-
vate the  PMNs itself.32,33 High  levels of  serum  IL-8
have been detected in various diseases and suggested
to be the marker of disease activity in sarcoidosis.34
This  study  also  showed  that  IL-8  levels  were  sig-
nificantly  higher  in  patients  with  BD  over  control
subjects.  In  addition,  IL-8  levels  were  significantly
higher  in  active BD  patients  when  compared with
inactive  subjects.  Since  IL-8  has  pro-inflammatory
properties  in  the  inflammatory  response  with  its
potent effect on neutrophils by attraction of  PMNs
into the lesions (a characteristic finding of BD), we
think that IL-8 most probably participates during the
course of BD. Considering the known properties of
IL-8 as a chemoattractant and activator of neutrophils,
the treatment of BD might be of immense value in the
development of therapeutic regiments for managing
the disease.
TNF  (17kDa)  is  a  cytokine secreted  by  lympho-
cytes and reticuloendothelial cells in many acute and
chronic inflammatory diseases.31TNF, like IL-6, is also
a pro-inflammatory cytokine and is involved in  the
blood–retinal  barrier  breakdown  by  opening  tight
junctions of retinal vascular endothelial cells and RPE
cells.35The present study showed that TNF-a levels in
the  serum  of  patients  with  BD  were  significantly
higher in active disease than inactive BD patients or
control  subjects.  It  is  probable  that  the  disease
activity  is  associated  with  the  secretion  of  pro-
inflammatory mediators by direct activation of circu-
lating monocytes.31
Increased free-radical production by activated neu-
trophils has been demonstrated in BD.36The burst of
activated, oxygen-derived free radicals is responsible
for cell  membrane  peroxidation, resulting  in  tissue
oedema with enzyme and protein degradation. Lipid
peroxidation, in turn, leads to the subsequent forma-
tion  of  free  fatty  acids  and  arachadonic  acid.3 A
vicious  circle  ensues,  whereby  the  metabolism  of
these molecules leads to further free-radical formation
and OH￿ generation, which may lead to further lipid
peroxidation in cells and further oxidative damage.37
This  study  clearly  found  that  lipid  peroxidation,
measured as MDA levels,  was increased in  patients
with  BD,  and  that  the  levels  were  correlated with
disease  activity. Therefore,  this  may  be  responsible
from the tissue damage in BD as well as endothelial
dysfunction, which is the most characteristic feature
of the disease.22,36 Defence systems of cells against
this free-radical-induced toxic lipid peroxidation con-
sist  of  antioxidant  molecules.38 These  molecules
block the initiation of free-radical chain reactions, and
therefore lipid peroxidation in cells.
Taken together, serum MDA, sIL-2R, IL-6, IL-8 and
TNF-a levels were significantly higher in patients with
active BD  compared with inactive BD  patients and
healthy control subjects. We concluded that endothe-
lial  cells,  PMNs  and  macrophages  produced  pro-
inflammatory cytokines such as IL-1b, IL-6, and TNF,
and these cytokines possibly induced inducible NO
synthase and, thereby, increased NO production.39 In
fact,  our  another  study  demonstrated an  increased
total nitrite level (an indicator of NO production) in
patients  with  BD  when  compared  with  control
subjects  with  the  highest  level  in  the  active  BD
patients.13 This most abundant free radical possibly
induces oxidative stress and leads to the formation of
self-propagating lipid peroxidation. On the contrary,
our further study found higher homocysteine levels in
patients with BD,12 which is known to be the potent
C. Evereklioglu et al.
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cysteine ® cytokine ® leptin ® nitric oxide ® lipid
peroxidation relationships during the course of  BD
are open to further in vivo and in vitro studies.
In conclusion, we observed increased mean levels of
MDA, sIL-2R, IL-6, IL-8 and TNF-a in patients with BD
over control subjects. Furthermore, sIL-2R, IL-6, IL-8
and TNF-a levels  in  patients  with  active  BD  were
significantly  higher  than  those  in  inactive  patients,
suggesting  that  these  cytokines  to  be  related  with
disease activity. These pro-inflammatory cytokines may
play a role during the course of the disease and may be
responsible for tissue damage by lipid peroxidation.
Understanding the role of these low molecular weight
proteins in a wider context should help us to clarify the
role of the chemokine and cytokines in the aetiopatho-
genesis of BD. Treatment of BD is presently difficult,
partly  because  of  the  multisystem  nature  of  the
disease. Recent treatment modalities are encouraging,
and it is probable that further treatment modalities that
interfere  with  cell  signalling  processes  may  be  the
future direction for the clinical management of BD. In
addition, amelioration of clinical manifestations may
be  envisaged  by  targeting  lipid  peroxidation  with
dietary or pharmacological antioxidants.
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